Hong Chen
Guangzhou University of Chinese Medicine(CN)The University of Texas MD Anderson Cancer Center(US)Nanjing Tech University(CN)Harvard University(US)National Taiwan University(TW)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Peking University(CN)Sichuan University(CN)Fudan University(CN)Peking Union Medical College Hospital(CN)Beijing Jishuitan Hospital(CN)Wuhan University(CN)West China Hospital of Sichuan University(CN)Fosun Pharma (China)(CN)Zhongnan Hospital of Wuhan University(CN)Peking University People's Hospital(CN)Changshu No.1 People's Hospital(CN)Chengdu Second People's Hospital(CN)Karamay Central Hospital of Xinjiang(CN)Huashan Hospital(CN)Qilu Hospital of Shandong University(CN)Southern Medical University(CN)Yangzhou University(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Chronic Obstructive Pulmonary Disease (COPD) Research, Respiratory Support and Mechanisms, Asthma and respiratory diseases, Immune cells in cancer
Most-Cited Works
- → VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer(2017)587 cited
- → CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients(2008)535 cited
- → Kimura Disease(2004)336 cited
- → FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients(2021)219 cited
- → Mechanotransduction activates canonical Wnt/β-catenin signaling to promote lymphatic vascular patterning and the development of lymphatic and lymphovenous valves(2016)141 cited
- → Abdominal compartment syndrome in patients with severe acute pancreatitis in early stage(2008)130 cited